Table 8.
Multivariable hazard ratios (HR) and 95 % confidence intervals (CIs) for risk of ovarian cancer by tertiles of 2-pathway and 4-pathway metabolites
| Estrogen/EM | Cases (n = 67) | Subcohort (n = 416) | HR (95 % CI) |
|---|---|---|---|
| 2-Pathway metabolites | |||
| 2-Catechols | |||
| T1 | 17 | 138 | 1.00 |
| T2 | 25 | 136 | 1.27 (0.64, 2.53) |
| T3 | 25 | 142 | 1.18 (0.61, 2.31) |
| p trend | 0.65 | ||
| 2-Hydroxyestrone | |||
| T1 | 17 | 137 | 1.00 |
| T2 | 24 | 138 | 1.19 (0.59, 2.40) |
| T3 | 26 | 141 | 1.23 (0.63, 2.39) |
| p trend | 0.55 | ||
| 2-Hydroxyestradiol | |||
| T1 | 20 | 137 | 1.00 |
| T2 | 20 | 137 | 0.93 (0.47, 1.85) |
| T3 | 27 | 142 | 1.15 (0.60, 2.22) |
| p trend | 0.65 | ||
| 2-Methylated catechols | |||
| T1 | 14 | 138 | 1.00 |
| T2 | 24 | 137 | 1.49 (0.72, 3.09) |
| T3 | 29 | 141 | 1.84 (0.92, 3.70) |
| p trend | 0.08 | ||
| 2-Methoxyestrone | |||
| T1 | 17 | 137 | 1.00 |
| T2 | 21 | 138 | 1.11 (0.55, 2.23) |
| T3 | 29 | 141 | 1.37 (0.70, 2.68) |
| p trend | 0.36 | ||
| 2-Methoxyestradiol | |||
| T1 | 17 | 138 | 1.00 |
| T2 | 19 | 137 | 0.96 (0.48, 1.95) |
| T3 | 31 | 141 | 1.67 (0.88, 3.18) |
| p trend | 0.11 | ||
| 3-Methoxyestrone | |||
| T1 | 20 | 137 | 1.00 |
| T2 | 23 | 137 | 1.32 (0.67, 2.63) |
| T3 | 24 | 142 | 1.21 (0.63, 2.32) |
| p trend | 0.57 | ||
| 4-Pathway metabolites | |||
| 4-Hydroxyestrone | |||
| T1 | 19 | 137 | 1.00 |
| T2 | 20 | 137 | 0.89 (0.45, 1.78) |
| T3 | 28 | 142 | 1.21 (0.63, 2.33) |
| p trend | 0.54 | ||
| 4-Methylated | |||
| T1 | 15 | 137 | 1.00 |
| T2 | 19 | 138 | 1.13 (0.52, 2.43) |
| T3 | 33 | 141 | 1.95 (0.97, 3.91) |
| p trend | 0.05 | ||
| 4-Methoxyestrone | |||
| T1 | 15 | 138 | 1.00 |
| T2 | 19 | 137 | 1.22 (0.58, 2.59) |
| T3 | 33 | 141 | 2.04 (1.01, 4.10) |
| p trend | 0.04 | ||
| 4-Methoxyestradiol | |||
| T1 | 20 | 138 | 1.00 |
| T2 | 25 | 136 | 1.04 (0.54, 2.01) |
| T3 | 22 | 142 | 1.00 (0.50, 2.01) |
| p trend | 1.00 | ||
The following tertile categories (T1, T2, T3 pmol/L) determined based on the distribution of each estrogen or estrogen metabolite among the subcohort: 2-catechols (<62.12, 62.12–86.90, >86.90), 2-hydroxyestrone (<50.87, 50.87–73.85, >73.85), 2-hydroxyestradiol (<10.80, 10.80–14.21, >14.21), 2-methylated catechols (<35.78, 35.78–54.78, >54.78), 2-methoxyestrone (<20.85, 20.85–34.67, >34.67), 2-methoxyestradiol (<10.21, 10.21–16.21, >16.21), 3-methoxyestrone (<3.55, 3.55–5.06, >5.06), 4-hydroxyestrone (<8.43, 8.43–12.07, >12.07), 4-methylated catechols (<5.59, 5.59–7.93, >7.93), 4-methoxyestrone (<3.46, 3.46–4.69, >4.69), 4-methoxyestradiol (<2.22, 2.22–3.45, >3.45); adjusted for clinic and trial participation status